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Abstract
Natural products (NPs) are an attractive source of chemical diversity for small-molecule drug discovery. Several challenges
nevertheless persist with respect to NP discovery, including the time and effort required for bioassay-guided isolation of
bioactive NPs, and the limited biomedical relevance to date of in vitro bioassays used in this context. With regard to
bioassays, zebrafish have recently emerged as an effective model system for chemical biology, allowing in vivo high-content
screens that are compatible with microgram amounts of compound. For the deconvolution of the complex extracts into
their individual constituents, recent progress has been achieved on several fronts as analytical techniques now enable the
rapid microfractionation of extracts, and microflow NMR methods have developed to the point of allowing the identification
of microgram amounts of NPs. Here we combine advanced analytical methods with high-content screening in zebrafish to
create an integrated platform for microgram-scale, in vivo NP discovery. We use this platform for the bioassay-guided
fractionation of an East African medicinal plant, Rhynchosia viscosa, resulting in the identification of both known and novel
isoflavone derivatives with anti-angiogenic and anti-inflammatory activity. Quantitative microflow NMR is used both to
determine the structure of bioactive compounds and to quantify them for direct dose-response experiments at the
microgram scale. The key advantages of this approach are (1) the microgram scale at which both biological and analytical
experiments can be performed, (2) the speed and the rationality of the bioassay-guided fractionation – generic for NP
extracts of diverse origin – that requires only limited sample-specific optimization and (3) the use of microflow NMR for
quantification, enabling the identification and dose-response experiments with only tens of micrograms of each compound.
This study demonstrates that a complete in vivo bioassay-guided fractionation can be performed with only 20 mg of NP
extract within a few days.
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Introduction
Natural products (NPs) are an important source of drug-like
compounds for the discovery of new therapeutic candidates and
over time their chemical diversity has contributed significantly to
the development of drugs for a wide range of diseases. The
majority of new drugs approved within the last thirty years are
either natural products themselves or are derived from natural
products [1–3].
Currently, most drug discovery programs are based on high-
throughput screening (HTS) to rapidly query the bioactivity of
large libraries of synthetic compounds. In contrast, the isolation
and characterization of bioactive secondary metabolites present in
complex NP extracts involves the application of several comple-
mentary methodologies that require considerably more time and
effort [4,5]. In addition, there are several inherent caveats
associated with testing NPs in HTS. Crude extracts from various
species of plants, fungi, and bacteria, herein after called NP
extracts, are complex mixtures of mostly uncharacterized com-
pounds, some of which might have undesired effects. The chemical
properties of certain secondary metabolites might hinder the test
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readout and interfering constituents present in the crude extract
can either mask the biological activity [6] or cause toxic effects that
lead to false positives, e.g. in enzymatic assays. Nevertheless, a
considerable advantage of NPs is their chemical diversity. The
chemical space occupied by NPs is different from the one occupied
by synthetic compounds – often with far greater degrees of 3-
dimensionality and structural complexity. NPs are a promising
source of diverse molecular scaffolds for the discovery of novel lead
compounds against original targets [7] and recently, combinatorial
libraries with NP-like compounds have been used for HTS [3].
Bioassay-guided fractionation has proven successful as a well-
established platform to isolate and characterize active constituents
present in NP extracts, which are then suitable for HTS [8,9].
However, such an approach requires multiple chromatographic
steps and large amounts of biological material. Recent technolog-
ical improvements in the area of chromatographic separation
methods have nevertheless provided new possibilities to accelerate
the overall process of bioassay-guided fractionation. In particular,
the development of microfractionation approaches based on
advanced high performance liquid chromatography (HPLC)
techniques is now enabling the systematic separation of complex
plant extracts using more widely applicable protocols [10]. The
increasing sophistication of such techniques by linking them
directly (on-line) or indirectly by adding an additional step of
sample concentration (at-line) with analytical assays allows the
more rapid dereplication of extracts – identifying known NPs prior
to thorough characterization – thereby focusing resources on novel
molecules.
Although active constituents present in NP extracts can now be
identified more quickly as less time is expended on the purification
of inactive constituents, still appreciable amount of time is invested
if the bioactive compounds need to be isolated for the
determination of their structure and in-depth biological testing.
This is the bottleneck of bioassay-guided isolation since the de novo
structure elucidation of small molecules relies on NMR spectros-
copy, which has intrinsically low sensitivity. Nevertheless, with the
emergence of microflow NMR [11] and cryo and microcryo NMR
technologies [12–14] used routinely in NP drug discovery, the
boundaries could be pushed to the low microgram scale of sample
needed for the acquisition of 1H-13C and 13C spectra.
When working with HPLC-based biological profiling, another
issue is to quantify the potency of a given extract constituent in a
given bioassay since the microgram quantities obtained by
microfractionation have to be correctly estimated [15]. Weighing
of the individual microfractions is not only impractical but also
inaccurate at sub-milligram quantities. Furthermore, compound
purity is not taken into account. Since NMR gives an absolute
signal response, it can not only provide unambiguous compound
identification but allows precise quantification even of unknown
compounds and estimate ratios in fractions still containing
mixtures. NMR quantification can be performed either with an
internal standard, using the ERETIC (electronic reference to
access in vivo concentrations) [16] method that demands special-
ized electronic equipment, or the PULCON (pulse length based
concentration determination) [17] method with reference to an
external standard.
The ultimate impact of these new methods on the field of NP
discovery, however, will be determined by the bioassays with
which they can be combined. The recent report of a micro-
fractionation approach involving the coupling of microbore HPLC
separation with an at-line 1536-well biochemical screening assay
for protein kinase A activity assessment and with parallel QTOF
MS (quadrupole time of flight MS) data acquisition for analyte
identification is an excellent example of the potential of this
technology [18].
Despite its utility for HTS of active compounds, the reliance of
such strategies on enzymatic or in vitro cell-based assays to assess
their biological activity limits the biomedical relevance of the
active metabolites isolated in this manner. By combining high-
resolution microfractionation with high-content assays, the activity
of the separated constituents would be analyzed and validated to
an appreciably higher degree.
In contrast with enzymatic or cell-based reporter assays, high-
content bioassays (e.g. phenotypic assays using cells or organisms)
allow the unbiased analysis of pharmacological activity. In
particular, in vivo animal models offer the possibility to screen for
biomedically relevant bioactivities in a target- and pathway-
independent manner. Nevertheless, mammalian models such as
rodents require larger amounts of compound (in the milligram
range) for activity analysis, and are therefore not ideal in vivo
platforms for rapid HPLC profiling and microfractionation
strategies.
In this context, zebrafish bioassays represent an attractive
alternative to determine the in vivo bioactivity of chromatographic
fractions containing only microgram amounts of individual
compounds. Zebrafish – Danio rerio – have recently emerged as a
reliable in vivo vertebrate model system for functional genomics
and drug discovery [19]. Beyond their many physiological and
pharmacological similarities to mammals, zebrafish have impor-
tant advantages such as high fecundity (up to hundreds of offspring
per day), the small size of embryos and larvae (0.5 to 5 mm
depending on the developmental stage), optical transparency and
rapid development ex utero. These features confirm zebrafish as a
versatile in vivo experimental model compatible with HTS and
microfractionation techniques in the field of NP discovery [20]. In
this regard, the amenability of using zebrafish embryos and larvae
in microtiter plates (96- and even 384- well design) allows early
in vivo analysis of the activity of small-molecule compounds isolated
by microfractionation approaches. Depending on the potency of
these isolated compounds, the requirement of only microgram
amounts to induce an initial biological response represents another
excellent benefit of using zebrafish as a model organism over other
higher vertebrates (e.g. rodents, in which the active dose
requirements are usually a thousand-fold higher [21]).
This latter feature is key for NP discovery, as many high-
resolution separation methods based on HPLC, particularly
microfractionation, result in very limited amounts of samples that
would otherwise be insufficient for the in vivo analysis of activity.
In this study we combine HPLC profiling with microfractiona-
tion and sensitive microflow NMR at-line detection with a high-
content in vivo screen in zebrafish for the rapid identification of
bioactive NPs in crude plant extracts as well as for the direct
estimation of their biological activity and potency at the
microgram level. We illustrate this approach by investigating both
the anti-inflammatory and the anti-angiogenic activity of a
Fabaceae plant used in traditional Tanzanian medicine, Rhynchosia
viscosa (Roth) DC. Optimization of the workflow with minimal
amounts of extract was successfully achieved providing a generic
approach that is adaptable for any other sample, even if extracts
are only available in milligram amounts (e.g. because the
phytochemical analysis is done on a herbarium sample, supply
of the extract is difficult or the biological species under
investigation is small in size).
Microscale Natural Product Discovery in Zebrafish
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Results and Discussion
Anti-inflammatory and Anti-angiogenic Activity of
Rhynchosia viscosa in Zebrafish
Using a zebrafish-based inflammation assay [22], we screened
crude methanolic extracts from over 80 East African medicinal
plants. The extract of Rhynchosia viscosa (Roth) DC. (Fabaceae)
inhibited leukocyte migration in tail-transected four days post-
fertilization (4 dpf) larvae in a concentration-dependent manner
(Figure 1). The anti-inflammatory effect of the crude extract of R.
viscosa was evident at 50 mg/mL – a concentration at which a
relative leukocyte migration (RLM) value of 0.39 was achieved
(Figure 1D), in comparison with an RLM of 0.24 achieved by
100 mM indomethacin as a positive control (Figure 1E). Interest-
ingly, the ethnomedicinal use of R. viscosa in Tanzania (local name:
mfundofundo) includes the topical treatment of inflammatory skin
disorders and insect bites (M. J. Moshi, personal communication),
prompting us to perform follow-up studies for the identification of
anti-inflammatory constituents of this plant.
In parallel, we also screened the extracts of these East African
medicinal plants for their capacity to inhibit angiogenesis, based
on their ability to restrict vascular outgrowth in fli-1:EGFP
transgenic zebrafish embryos [23], which exhibit vasculature-
specific expression of enhanced green fluorescent protein (EGFP)
during embryonic and larval development. In addition to the
identification of Oxygonum sinuatum (Meisn.) Dammer (Polygona-
ceae) and Plectranthus barbatus Andrews (Lamiaceae) as anti-
angiogenic extracts [24], we found that the methanolic extract
of the aerial parts of R. viscosa inhibited intersegmental vessel (ISV)
outgrowth in fli-1:EGFP embryos in a concentration-dependent
manner (Figure 2). In order to rapidly localize the compounds
responsible for the bioactivity, high-resolution HPLC-based
bioassay-guided fractionation of the extract was performed using
the zebrafish vascular outgrowth assay given its higher throughput
and lower assay volume compared to the lipopolysaccharide
(LPS)-enhanced leukocyte migration assay.
Generic Chromatographic Procedure for Optimal One-
step Microfractionation of NP Extracts for the Rapid
Localization of Bioactive Constituents
For the rapid isolation and identification of the bioactive
constituents of R. viscosa we developed a generic chromatographic
procedure which combines (1) ultra high pressure liquid chroma-
tography – photo diode array – time of flight mass spectrometry
(UHPLC-PDA-TOFMS) for extract profiling, (2) gradient transfer
for one-step separation on semi-preparative HPLC and (3)
microfractionation for a rapid collection of all LC peaks for
further bioactivity assessment (Figure 3).
UHPLC-PDA-TOFMS Profiling and Dereplication
Initially, a metabolite profiling at the analytical scale was
performed with microgram amounts of crude extract on UHPLC-
PDA-TOFMS to evaluate the extract complexity. This method
combines high-resolution separation on sub-2 mm particle col-
umns with high-resolution MS detection, which provides molec-
ular formula information for all analytes on-line [25]. For this
generic profiling, the separation was achieved on an enriched
extract with optimal conditions for maximal peak capacity [26]
(Figure 3A). The metabolite profiling revealed a large number of
detected peaks to have PDA spectra corresponding to polyphenols
with molecular weights ranging from 250 to 450 Da. Most of the
PDA spectra were characteristic for either flavones or isoflavones,
both known to be present in the Fabaceae family [27]. The high-
resolution MS data gained from the UHPLC-PDA-TOFMS
analysis provided molecular formula information for all detected
LC peaks giving a first overview of the extract composition. This
preliminary structural information was later used in combination
with the bioassay results for the dereplication of the bioactive
constituents.
Determination of Generic Parameters for
Microfractionation
In order to rapidly determine which compounds were
responsible for the bioactivity of the enriched extract, a
microfractionation strategy was developed to enable the acquisi-
tion of fractions in 96-well plate format with sufficient quantities
Figure 1. Anti-inflammatory activity of the methanolic extract of Rhynchosia viscosa. Anti-inflammatory activity was determined in an acute
inflammation assay based on tail transection and treatment with lipopolysaccharides (LPS). A to D, zebrafish larvae are 4 days post-fertilization (dpf)
with anterior to the left, scale bar = 10 mm. After tail transection and LPS exposure, stained leukocytes appear as black-brown spots migrating to the
injured area in the transected tails. Migrating leukocytes were counted on one side in the tail in the region to the right of the dashed red arc and
migration values were expressed as relative leukocyte migration (RLM) (E). A, tail of an uncut larva; B, negative control (DMSO 1%); C, positive control
(indomethacin 100 mM) D, crude extract of R. viscosa at 50 mg/mL; E, graph displaying the RLM of 4 dpf larvae (n = 10) subjected to tail transection
and incubation with R. viscosa. RLM #0.5 was established as cutoff for anti-inflammatory activity. * p,0.05.
doi:10.1371/journal.pone.0064006.g001
Microscale Natural Product Discovery in Zebrafish
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both for bioactivity testing (anti-angiogenic assay) and for
structural elucidation (high-resolution MS and 1H NMR analysis)
of the bioactive compounds at the analytical level, starting with
only a few milligrams of extract. According to the sensitivity of the
zebrafish anti-angiogenic assay which was deduced from several
known anti-angiogenic compounds with a range of in vivo
potencies in zebrafish including SU5416 and emodin [24], it
was estimated that the microfractionation procedure should yield
at least 1 mg per well for an initial tracking of the anti-angiogenic
activity over the entire chromatogram. On the other hand, since
compound identification was foreseen based on microflow 1H
NMR, it was necessary to keep a minimum of 5 mg for further
dereplication. In addition, as the bioassay is carried out in a 96-
well plate format that includes controls, the number of fractions
had ideally to be 90 or a multiple thereof.
In order to obtain 5–10 mg per microfraction, it was estimated
that 1.5 mg of enriched extract would be required. The loading
was multiplied by a factor of 10 to ensure that most of the activity
could be assessed and minor bioactive constituents could be
detected, factoring in the recovery of a given metabolite through
microfractionation on reversed phase (RP) columns is , 70% (see
Text S1). It was thus estimated that 20 mg of enriched extract
would be sufficient for the entire microfractionation procedure
and a column with an adapted loading capacity was selected. To
minimize sample handling, fractions were collected directly into
96-deepwell plates, facilitating the subsequent drying of all samples
at once by vacuum centrifugation, whereas a maximum volume of
1.2 mL of eluent per well had to be respected.
A column geometry of 250610 mm was found to be a good
compromise between loading capacity, HPLC resolution and
microfraction volumes. In order to fill the deepwells with adequate
eluent volumes and collect peaks with sufficient resolution, a
fraction collection time of 30 sec and a flow rate of 2.3 mL/min
were chosen.
Based on the gradient time constraints of the microfractionation
procedure (90 min6180 microfractions), corresponding gradient
time and flow rate were calculated for the analytical UHPLC
(gradient time 11.4 min, flow rate 306 mL/min). This was
necessary to optimize the gradient for the separation of the NPs
in a specific extract at the analytical scale. For a good
predictability of the separation efficiency between UHPLC and
semi-preparative HPLC, the same phase chemistry and columns
geometries with similar theoretical peak capacities [28] were
chosen (see Materials & Methods).
All of these steps are generic, as the procedure is adaptable for
any medium-polar extract compatible with RP separation.
Separation Optimization Specific to Rhynchosia viscosa
and Microfractionation
Since all generic parameters were fixed by the requirements of
the bioassay and the structure identification, only the solvent
system and the gradient needed to be adapted for profiling.
Therefore, the chromatographic gradient method for the micro-
fractionation was optimized on UHPLC-PDA-TOFMS by adapt-
ing the generic profiling gradient to maximize mixture component
resolution over the run time allowed by the collection. In the case
of R. viscosa, a linear gradient from 40% to 90% methanol (MeOH)
was optimal (Figure 3B) (see Materials & Methods). This gradient
was directly transferred to the semi-preparative system. The
enriched extract (19.8 mg) was chromatographed in one step
(Figure 3C) and 180 microfractions were generated and collected
into 96-deepwell plates. Each microfraction (1.15 mL total
volume) was divided into three aliquots: for the zebrafish
angiogenesis assay (115 mL, 10% of the total volume, aliquot A);
for LC-MS analysis (11.5 mL, 1% of the total volume, aliquot B);
and for microflow NMR analysis (ca. 1.12 mL, 89% of the total
volume, aliquot C).
Figure 2. Anti-angiogenic activity of the methanolic extract of Rhynchosia viscosa. Inhibition of vascular outgrowth was determined in fli-
1:EGFP transgenic embryos. At 16 hours post-fertilization (hpf), embryos were incubated with different concentrations of the methanolic extract of
the plant and anti-angiogenic effects were assessed at 48 hpf. A to C, all embryos are 48 hpf, with anterior to the left, scale bar = 10 mm. A, untreated
control (DMSO 1%); B, zoom of A (dashed box) showing normal outgrowth of intersegmental vessels (ISV) along the trunk of the larva (arrows); C,
embryo treated with 50 mg/mL crude methanolic extract of R. viscosa. Inhibition or reduction of ISV growth is observed along the trunk (arrows); D,
IC50 curve and values showing the inhibitory activity of the methanolic extract of R. viscosa.
doi:10.1371/journal.pone.0064006.g002
Microscale Natural Product Discovery in Zebrafish
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Figure 3. Generic procedure for the rapid identification of bioactive constituents from medium polar plant extracts. A, Generic ultra
high pressure liquid chromatography – photo diode array – time of flight mass spectrometry (UHPLC-PDA-TOFMS) chromatogram. UHPLC conditions:
Acquity BEH C18 column (15062.1 mm i.d., 1.7 mm); A: 0.1 vol% formic acid (FA)-H2O, B: 0.1 vol% FA-acetonitrile, 5–95% B in 309; 0.46 mL/min; ESI-MS
detection in negative ion (NI) mode; B, Optimized UHPLC-PDA-TOFMS chromatogram for methanolic extract of R. viscosa. UHPLC conditions: Acquity
BEH C18 column (10062.1 i.d., 1.7 mm); A: 0.1 vol.% FA-H2O, B: 0.1 vol% FA-methanol (MeOH), 40–90% in 11.49; 0.306 mL/min, ESI-MS detection in NI
Microscale Natural Product Discovery in Zebrafish
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Anti-angiogenic Screen of Microfractions
Microfractions were screened for anti-angiogenic activity using
the zebrafish-based vascular outgrowth assay described above. In
an initial screen, 60% of each aliquot A (equivalent to 70 ml of the
original 115 ml) was used. Inhibition was observed as the absence
or reduction of vascular outgrowth. Microfractions inducing
complete inhibition of vascular outgrowth or embryonic toxicity
were tested at one third of this concentration (20% of each aliquot
A, equivalent to 23 ml of the original 115 ml). This in vivo biological
profiling revealed six main chromatographic zones containing
anti-angiogenic compounds at high concentration (30.0–33.0 min,
54.5–55.0 min, 56.5–57.0 min, 60.5–61.0 min, 66.5–68.5 min,
71.5–72.5 min and 79.5 min) (Figure 3D). When testing at the
lower concentration, only four zones (30.0–33.0 min, 54.5–
55.0 min, 56.5–57.0 min and 60.5–61.0 min) were still active
(data not shown). To rapidly identify the constituents responsible
for the anti-angiogenic activity and to estimate the amount tested
in the corresponding microfractions, 1H NMR spectra were
recorded using microflow NMR.
Rapid Compound Identification in Bioactive
Microfractions
In the first active chromatographic zone, ten consecutive
microfractions were found to inhibit angiogenesis (80–100%
inhibition of vascular outgrowth at high concentration). The MS
data recorded during microfractionation indicated a nominal mass
of m/z 269 [M-H]– for the main compound eluting in this region.
The corresponding exact mass recorded during the UHPLC-PDA-
TOFMS profiling of the extract was m/z 269.0461 (compound a)
indicative of the molecular formula C15H10O5 (calc. m/z
269.0450, D 4.1 ppm). This was also validated by application of
heuristic filtering [29,30] (see Materials & Methods). A cross
search with this molecular formula and with chemotaxonomic
information (Fabaceae, Leguminosae) in the Dictionary of Natural
Products (DNP) [31] revealed that a could correspond to 7,39,49-
trihydroxyflavone or 5,7,49-trihydroxyisoflavone (genistein). In
addition, the PDA spectrum presented an absorption maximum
(lmax) at 260, 290 sh and 325 sh nm characteristic for isoflavones
such as genistein. Compound a was easily confirmed to be
genistein (Figure 4) by the comparison of the 1H NMR spectrum
of the corresponding microfraction obtained by microflow NMR
(CapNMRTM) with literature values [32]. In all the fractions
collected in the 30.0–33.0 min region, the 1H signals of genistein
were present confirming it to be responsible for the in vivo anti-
angiogenic activity observed (Figure 3D).
The last two microfractions in this first zone contained another
constituent with m/z 299.0549 (compound e) consistent with the
molecular formula C16H12O7, and possibly another isoflavone
derivative based on the dereplication by TOFMS and PDA (calc.
m/z 299.0556, D 2.3 ppm, lmax 260, 290 sh, 340 sh nm). The
identification of this isoflavone was based on interpretation of the
corresponding additional 1H signals to those of genistein in this
microfraction. The presence of a methoxy substituent (d 3.90) was
revealed and its position at C-39 was confirmed by comparison
with reported data [33]. The molecule was finally identified as 39-
O-methylorobol. Further bioactivity analyses were not undertaken
for this constituent as the molecule was not isolated as a pure
compound but only in a mixture with genistein.
In the second active zone of the chromatogram, the two
microfractions contained one single constituent (compound b)
with m/z 477.1195 ([M-H]– C26H22O9, calc. m/z 477.1186, D
1.9 ppm). A database search yielded six NPs with this molecular
formula but none were isolated from Fabaceae species, nor were
they consistent with the 1H NMR spectrum of b. The complete
structure of this polyphenol could not be determined de novo only
based on these data. The compound was named rhynchoviscin
and its full structural identification is discussed below in the section
‘‘De novo identification of the novel compound b’’.
In the third zone, the two microfractions contained another
constituent (compound c) with m/z 351.0886 ([M-H]–, C20H16O6,
calc. m/z 351.0869, D 2.0 ppm) and with aromatic 1H signals
typical of an isoflavone. This molecular formula matched with
more than 100 possibilities in DNP and no hypothesis could be
deduced. The 1H NMR spectrum in deuterated methanol
(methanol-d4) was consistent with the configurational isomers
licoisoflavone B and sophoraisoflavone A. An additional experi-
ment by re-dissolution of the microfraction in acetone-d6
confirmed that it was sophoraisoflavone A (Figure 4) by
comparison of the 1H chemical shift of 5-OH (d 13.07) [34].
In the fourth zone, two microfractions contained one major
constituent (compound d) with m/z 353.1037 ([M-H]–, C20H18O6,
calc. m/z 353.1025, D 3.4 ppm) consistent with prenylated
isoflavone derivatives. Beside the aromatic protons characteristic
for isoflavones, 1H signals characteristic for a prenyl group were
detected (two methyl signals (d 1.66 and 1.77) correlating to a vinyl
proton (d 5.25) and further connected to a downfield-shifted
methylene group (d 3.38), as determined by 2D NMR).
Comparison of chemical shifts with literature data [35] confirmed
d to be licoisoflavone A (Figure 4).
At the high concentration, three more active zones were
detected for compounds eluting after 66 min (Figure 3D). No
exploitable NMR spectra could be recorded (no aromatic signals
were detected) in the corresponding microfractions, and the
activity was not seen when tested at the low concentration. These
microfractions were not further studied.
Quantification of Bioactive Molecules and Correlation
with Anti-angiogenic Activity
To rapidly evaluate the potency of the bioactivity measured, a
reliable estimation of the concentration present in each tested
microfraction was made. In order to be generic and not have to
depend on standards, NMR was used for quantification. Micro-
flow NMR was found to be well-suited for the limited sample
amounts present in the microfractions.
mode; C, Semi-preparative high performance liquid chromatography (HPLC) chromatogram for the microfractionation of the enriched extract of R.
viscosa. HPLC conditions: XBridgeTM BEH C18 column (250610 mm i.d., 5 mm); A: 0.1 vol.% FA-H2O, B: 0.1 vol% FA-MeOH, 40–90% in 74.99; 2.3 mL/
min; ESI-MS detection in NI mode. The chromatographic gradient is geometrically transferred using mathematical models to obtain a comparable
elution of extract constituents. Fractions were collected every 30 s directly into 96-deepwell plates. The so generated microfractions were aliquoted
for anti-angiogenic screening (10% aliquot A), for fast LC-MS analysis (1%, aliquot B), and for NMR analysis (89%, aliquot C); D, Anti-angiogenic screen
on 180 microfractions generated by microfractionation. Positive bars show inhibition of angiogenesis of microfractions tested at high concentration;
negative bars show inhibition of angiogenesis of selected microfractions at 25 mM. The concentration was determined by quantitative NMR (qNMR)
(H); E, Determination of IC50 using the quantitative information obtained by qNMR (H); F, On-line PDA and high-resolution MS information from (A)
for the dereplication of plant constituents; G, 1H NMR spectra using the CapNMRTM probe for structure confirmation of bioactive constituents; H,
Integration of well resolved aromatic protons for quantification of bioactive constituents to establish the potency of the anti-angiogenic and anti-
inflammatory activity of the targeted compounds (D, E).
doi:10.1371/journal.pone.0064006.g003
Microscale Natural Product Discovery in Zebrafish
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Quantitative Microflow NMR
For NMR quantification a strategy that does not alter the
sample by addition of an internal standard was favored so that any
interference with bioassays is avoided. In this respect, a
quantitative NMR (qNMR) method using an external calibration
(PULCON [17]) was used. Further information on PULCON and
the validation of the qNMR method are given in the Text S2.
Overall, the microflow qNMR method (1) provides a universal
detection, (2) provides accurate estimation of sample amount in
the microgram range without need of any reference compounds,
and (3) is compatible with in vivo bioassays enabling fast and
reliable identification of bioactive NPs.
Quantification of Bioactive Constituents of Rhynchosia
viscosa
The optimized qNMR parameters were used for the acquisition
of the 1H NMR spectra of R. viscosa and thus, within the same
experiment, both identification and quantitative information could
be obtained for all microfractions displaying anti-angiogenic
activities. The proton signal chosen for quantification of all the
polyphenols corresponded to an aromatic proton signal on cycle B
well isolated from interfering signals (Figure 3H). Quantifiable
amounts were between 3 and 90 mg per microfraction. A
maximum analysis time of 50 min (128 transients) was found to
be a good compromise between throughput and detection limits.
For the bioactive compounds (a to d), the microfractions
containing the greatest amounts were the following: a (32.5 min,
87 mg), b (54.5 min, 50 mg), c (56.5 min, 35 mg), d (61.0 min,
55 mg). These sub-milligram amounts could be readily converted
into precise concentrations for determination of IC50 values in the
bioassays, since molecular weight in each case was known from the
LC-MS results. Thus, even at this stage, a good estimation of the
bioactive potency of the unknown compound b could be
established.
Assessment of the Purity of Microfractions by Fast
UHPLC-PDA-TOFMS
Prior to bioassay analysis and in parallel to NMR analysis, the
purity of the microfractions selected for IC50 measurements was
also determined using a fast UHPLC-PDA-TOFMS analysis using
aliquot B kept from the microfractionation (see above). This
revealed that the microfractionation generated always at least one
microfraction containing only one constituent for compounds a to
d. This also validates the reasoning to choose a collection strategy
of 30 sec per microfraction.
This indicated that the strategy chosen was able to rapidly
generate pure microfractions with well-defined quantities of
compounds to be evaluated biologically in the low microgram
range.
Anti-angiogenic and Anti-inflammatory Activity of
Compounds a to d
In the initial screen of the microfractions, a rapid localization of
the bioactive constituents in the extract could be efficiently
established (Figure 3D). This screen, however, provides informa-
tion on how the initial activity of the extracts is distributed among
its constituents based on their relative abundance in the extract.
Now, since the purity and the amount of each compound in each
microfraction is known from qNMR and MS analysis, a reliable
evaluation of the potency of the activity could be performed for the
determination of IC50 values.
For this, aliquot C of each microfraction (89% of the original
1.15 ml, which was previously used for NMR analysis) was
recovered and used to make a fixed-concentration solution in
dimethyl sulfoxide (DMSO) to perform a concentration-response
analysis and determine IC50 values for anti-angiogenic activity for
compounds a to d. Genistein (a) and licoisoflavone A (c) displayed
similar levels of potency, with IC50 values of 24.2 mM and
16.7 mM, respectively. Sophoraisoflavone A (d) and rhynchoviscin
(b) were less potent but still clearly anti-angiogenic, with IC50
values of 50.7 mM and 41.3 mM, respectively (Figure 5). All four
Figure 4. Anti-angiogenic constituents of methanolic extract of Rhynchosia viscosa. Compounds a and c exhibit anti-angiogenic and anti-
inflammatory activity.
doi:10.1371/journal.pone.0064006.g004
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compounds phenocopied the anti-angiogenic effects of the
R. viscosa extract in this assay (Figure 2).
Since the crude extract also exhibited anti-inflammatory
activity, compounds a to d were also assessed using the LPS-
enhanced leukocyte migration assay in zebrafish larvae. Moderate
but significant inhibition of leukocyte migration was observed for
genistein and sophoraisoflavone A at 12.5 and 25 mM (Figure 6B–
C). Intriguingly, no significant anti-inflammatory activity was
observed for licoisoflavone A or rhynchoviscin, indicating some
structure-dependent activity differences between these related
compounds (data not shown).
Genistein, an isoflavone synthesized by Fabaceae species and
usually derived from soybeans, inhibits the tyrosine kinases EGFR
(epidermal growth factor receptor), pp60v2src, and pp110gag2fes at
pharmacological doses, with negligible effects against serine/
threonine kinases such as protein kinase A, protein kinase C, and
phosphodiesterase [36]. With regard to its role in inflammation,
genistein inhibits LPS-induced nitrite production by cultured
macrophages and protects against LPS-induced necrosis by
reducing nitric oxide release via the downregulation of inducible
nitric oxide synthase [37]. Genistein also inhibits leukocyte-
endothelium interaction, thereby modulating vascular inflamma-
tion, and reduces reactive oxygen species (ROS) by attenuating the
expression of ROS-producing enzymes [38].
Regarding its role in angiogenesis, genistein as well as other
isoflavones are known to inhibit mammalian endothelial cell
proliferation and migration in vitro [39,40]. In vivo, genistein has
been found to inhibit angiogenesis in mouse models of melanoma
and breast cancer [41] and to inhibit retinal neovascularization, as
well as to downregulate vascular endothelial growth factor (VEGF)
and hypoxia-inducible factor (HIF1a) expression, in a mouse
model of oxygen-induced retinopathy [42].
To date, no anti-angiogenic or anti-inflammatory activity has
previously been reported licoisoflavone A and sophoraisoflavone
A.
In the initial screen, the inhibition of angiogenesis was
dependent on the original amount of each constituent in the
extract. The qNMR results enable the correlation of compound
amounts with bioactivity. For genistein, the analysis revealed the
anti-angiogenic activity of each microfraction to correlate well
with its calculated amount and thus the bioactivity profile in the
initial screen had a direct quantitative link with this compound.
For compounds b, c and d, similar activities were observed in the
primary screen for microfractions containing these pure com-
pounds, and these results were consistent with the subsequent IC50
analysis for each molecule – indicating the ability of this in vivo
approach to identify microgram-level quantities of NPs possessing
only moderate levels of bioactivity.
De Novo Identification of the Novel Compound b
During the first phase of dereplication and microfractionation
compound b could not be identified. Given that no phytochemical
analysis has been reported for R. viscosa and that the anti-
angiogenic activity of b was moderate, large scale isolation using a
MS-targeted fractionation yielded 420 mg of b. The NMR spectra
of b obtained from the large scale isolation matched the ones
obtained during the first microfractionation. A splitting of some of
the NMR signals was indicative of the possible presence of two
Figure 5. Bioactive compounds of Rhynchosia viscosa in the vascular outgrowth assay. IC50 curves and values were determined for each of
the bioactive constituents of the methanolic extract of R. viscosa. Each compound, at six different concentrations, was assessed for their effect in the
inhibition of intersegmental vessel (ISV) growth. A to F, all embryos are 48 hours post-fertilization (hpf), with anterior to the left, scale bar = 10 mm. A,
untreated control (DMSO 1%); B, zoom of A (dashed box) showing normal outgrowth of intersegmental vessels (ISV) along the trunk of the larva
(arrows); C, embryo treated with 50 mM genistein; D, embryo treated with 100 mM rhynchoviscin; E, embryo treated with 50 mM licoisoflavone A; F,
embryo treated with 50 mM sophoraisoflavone. Arrowheads point the interconnection zone between the dorsal aorta and the posterior cardinal vein,
arrows point the ISV; G, IC50 curves and values (mM) for each of the bioactive compounds of R. viscosa.
doi:10.1371/journal.pone.0064006.g005
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isomers. Attempts to separate these two isomers using high-
resolution isocratic conditions were not fruitful and structure
identification was thus performed on the mixture by extensive 2D
and 13C NMR spectroscopy (Figure S1).
Proton and carbon signals were assigned with the help of 1H,
COSY, HSQC, HMBC (short and long range) and APT
experiments recorded in deuterated DMSO (DMSO-d6).
The 1H NMR spectrum showed signals of two 1H pairs of a 4-
oxy-phenyl group at dH 7.20/7.24 (d, J = 8.6 Hz) and 6.74 (d,
J = 8.6 Hz), a tetra-substituted phenyl ring with the two proton
signals at dH 6.09 (d, J = 1.4 Hz) and 5.96 (d, J = 1.4 Hz), a penta-
substituted aromatic ring with a proton at dH 5.94, a dihydrofuran
ring substituted by two tertiary methyl and a secondary methyl
group (dH 0.94/0.97 (3H, s), 1.18/1.21 (3H, s), 1.24/1.26 (3H, d,
J=6.4 Hz) and 4.40/4.47 (1H, q, J=6.4 Hz)) and five hydroxyl
groups (dH 6.19/6.23 (1H, s), 9.38 (1H, brs), 9.63 (2H, brs) and
12.09 (1H, brs)). These signals were consistent with the skeleton of
a benzodihydrofuran fused to a benzodihydropyran with a phenyl
ring attached to the junction between furan and pyran ring
(Figure 4). This skeleton has been found in biflavonoids from
Daphne giraldii [43].
A long-range HMBC experiment showing a correlation
between the carbon C-2’’ and the hydroxyl group 3-OH as well
as H-6’’ and H-4’’ protons confirmed that the tetra-substituted
ring is linked to the dihydrofuran with the hydroxyl group 3-OH.
On the other side, 3JCH HMBC correlations between carbon C-6
with H-8 and the tertiary methyl groups attached the dihydrofuran
to the penta-substituted aromatic ring. Its linkage in position 6, 7
(instead of 5, 6) was confirmed by the downfield shift of the
hydroxyl proton (5-OH) at dH 12.09 indicating a hydrogen bridge
between 5-OH and the carbonyl C-4.
Several peaks (H-5’’’, H-4’’’, H-3’’’, H-2’’’, H-6’’, 3-OH, H-2’,
H-6’) were doubled and the carbon atoms affected were located on
the methylated dihydrofuran ring (C-1’’’ – C-5’’’), the phenol
moiety (C-1’ – C-6’) and the bridged carbon atoms between the
dihydropyran and the dihydrofuran ring (C-2 and C-3). This could
indicate that stereoisomerism is located at the bridge between the
dihydropyran and the dihydrofuran rings as observed for similar
biflavonoids where the structure was established by X-ray on the
co-crystals of the stereoisomeric mixture [43]. Thus, b corresponds
to a very rare skeleton and this new compound was named
rhynchoviscin; its structure as well as the ones of a, c, d and e are
given in Figure 4.
Conclusion
The known anti-inflammatory and anti-angiogenic activities of
genistein provide an initial validation of our NP discovery
approach. We used in vivo zebrafish-based assays to screen crude
plant extracts and subsequently, perform UHPLC-PDA-TOFMS
profiling and bioassay-guided microfractionation to isolate the
bioactive constituents of R. viscosa. These were then structurally
elucidated via high-resolution MS and microflow NMR.
Applying this generic miniaturized procedure, the phytochem-
ical analysis and the generation of microfractions for biological
evaluation of an NP extract and its individual constituents is
feasible within one day. An initial evaluation of the biological
profile of a given NP extract and its constituents is therefore
achievable within approximately one week in high-content
zebrafish-based bioassays.
This strategy represents a substantial acceleration of the NP-
based drug discovery process and allows valuable resources
required for the isolation of larger amounts of bioactive molecules
for testing in mice to be dedicated only towards extracts having
already demonstrated promising bioactivity in vivo at the micro-
gram scale.
The key advantages of this approach are the microgram scale at
which both biological and analytical experiments can be
performed and the speed and the rationality of the bioassay-
guided fractionation, which are generic for NP extracts of diverse
origin, and require only limited sample-specific optimization [44].
Moreover, TOFMS and microflow NMR data enable dereplica-
tion early in the NP discovery process, and the systematic use of
in vivo assays enables the identification of natural products with
Figure 6. Anti-inflammatory effect of genistein and sophoraisoflavone A. A to C, zebrafish larvae are 4 dpf (days post-fertilization) with
anterior to the left, scale bar = 10 mm. Migrating leukocytes were counted on one side in the tail in the region to the right of the dashed red arc and
migration values were expressed as relative leukocyte migration (RLM) (C). A, negative control (DMSO 1%); B, genistein 25 mM; C, sophoraisoflavone
A 25 mM; D, graph displaying the RLM in 4 dpf larvae (n = 10) after treatment with genistein and sophoraisoflavone A. RLM #0.5 was established as
cutoff for anti-inflammatory activity. * p,0.05.
doi:10.1371/journal.pone.0064006.g006
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novel bioactivities that to date could not readily be determined
through traditional assays.
In addition to genistein, bioactive constituents of R. viscosa
included licoisoflavone A and sophoroisoflavone A – isoflavone
derivatives that are structurally closely related. The novel
compound identified by this study, rhynchoviscin, indicates the
potential of this integrated approach to also identify bioactive NPs
that occur only in limiting quantities, and which have only
moderate bioactivity. Overall, these initial results demonstrate the
potential of zebrafish bioassay-guided microfractionation, in
combination with high-resolution MS and sub-milligram NMR
techniques, to rapidly identify bioactive NPs and to quantitatively
determine their in vivo bioactivity.
Materials and Methods
Ethics Statement
Permission to collect R. viscosa was granted by the Muhimbili
University of Health and Allied Sciences in Dar es Salaam,
Tanzania. Permission by local or federal government authorities
was not required to collect this species on public land.
Furthermore, as R. viscosa is not a protected or endangered
species, the collection of this species for any purpose, including for
scientific research, is not regulated.
All animal procedures were performed in accordance with
Belgian and European Laws, guidelines and policies for animal
experimentation, housing and care (Belgian Royal Decree of 6
April 2010 and European Directive 2010/63/EU on the
protection of animals used for scientific purposes of 20 October
2010). This project was approved by the Animal Ethics Committee
of the University of Leuven (approval number P101/2010).
General Experimental Procedures
Molar extinction coefficients were determined on a Perkin
Elmer UV/VIS Lambda 20 spectrometer and calculated based on
the quantities determined by NMR.
Chemicals & Compounds
Solvents used for sample preparation were MeOH from VWR
(HiPerSolv CHROMANORM), ultrapure water (Direct-Q 3 UV
water purification system, Millipore), and dichloromethane (DCM,
VWR). For the HPLC isolation step, solvents were HPLC grade
MeOH Chromanorm from VWR, formic acid (FA, 98%) from
Fluka and ultrapure water (Millipore). ULC/MS grade MeOH,
acetonitrile (ACN), H2O and FA (99%) from Biosolve was used for
the UHPLC-PDA-TOFMS analyses. For the NMR experiments,
methanol-d4 (99.8% atom deuterium), acetone-d6 and DMSO-d6
(99.9% atom deuterium) was obtained from Armar Chemicals and
Cambridge Isotope Laboratories Inc. respectively. Genistein (99%
pure) was obtained from Acros Organics and maleic acid
(ReagentPlusH .99.0%) from Sigma-Aldrich. For the bioassays,
1-phenyl-2-thiourea (PTU) and tricaine (ethyl 3-aminobenzoate)
were purchased from Sigma-Aldrich, DMSO from Acros Organ-
ics.
Plant Material, Extraction, Prepurification
Rhynchosia viscosa (Roth) DC. was collected on public land in
Tabora, Tanzania and a voucher specimen (number HOS 3119)
was deposited at the Faculty of Pharmacy of the Muhimbili
University of Health and Allied Sciences (MUHAS), Dar es
Salaam, Tanzania. The plant material was dried at room
temperature and ground. The dry, powdery plant sample was
exhaustively extracted with MeOH by maceration. The dry
methanolic extract was obtained after removing the solvent by
evaporation under reduced pressure. Prior to testing, an aliquot of
the dry methanolic extract was suspended in 100% DMSO; this
stock solution was then kept at -20uC.
The crude methanolic extract of R. viscosa was dissolved in 80%
aq. MeOH and purified by SPE (ZEOprep 60, C18, 40-63 mm,
Zeochem AG) using 80% aq. MeOH. Then, the sample was
solubilized in 95% aq. MeOH and eluted over a polyamide-filled
cartridge with 95% aq. MeOH that was pre-conditioned with
MeOH and 95% aq. MeOH [45] to remove tannins from the
extract. The sample was evaporated to dryness under reduced
pressure and a reddish solid as well as an orange oil was obtained.
This sample was extracted with DCM for enrichment and the
remaining part was used for microfractionation.
Microfractionation by Semi-preparative LC-MS
The enriched extract (19.8 mg) was redissolved in pure MeOH,
filtered over a 0.45 mm Nylon 66 syringe filter (BGB Analytik AG)
and fractionated by means of semi-preparative HPLC. The
gradient method was transferred using HPLC Calculator v3.0
[28]. The separation was accomplished on a Varian modular
HPLC system with a Varian 9012 pump coupled through a
Thermo Scientific electrospray ionization (ESI) interface to an ion
trap mass spectrometer instrument (LCQ, Thermo Scientific) and
a UV detector (at 254 nm, 2151 variable wavelength monitor,
LKB Bromma) to monitor the separation. A splitter enabled
50 mL/min of the flow coming from the HPLC to enter the mass
spectrometer. The following negative ionization-ESI (NI-ESI)
conditions were used: capillary temperature, 200uC; capillary
voltage, 238 V; spray voltage, 3 kV; tube lens offset, 23 V. The
acquisitions were performed in NI mode using a full scan mode
over an m/z range of 150–1000. An in-source fragmentation
energy of 5 V was applied. The separation was performed on a
250610 mm i.d., 5 mm, XBridgeTM BEH C18 column (Waters) in
gradient mode at 2.3 mL/min with the following solvent system:
A=0.1 vol% FA-H2O, B=0.1 vol% FA-MeOH; 40% B for
3.4 min and 40–90% B in 74.7 min and 90% B for 12 min. The
injected volume was 500 mL. Fractions of 1.15 mL were collected
every 30 s with a Gilson FC204 Fraction Collector directly into
conical-bottom 96-deepwell plates (VWR). An aliquot of each
microfraction (115 mL; 10% of the total microfraction volume,
aliquot A) from the semi-preparative isolation step was transferred
to a 96-well plate (Nunc, V96, PP, 0.45 mL), dried in a vacuum
centrifuge (Genevac HT-4X, Genevac Inc.) and used for
bioactivity testing in zebrafish. Another aliquot of each micro-
fraction (11.5 mL; 1% of the total microfraction volume, aliquot B)
was transferred to a 96-well plate (Nunc, V96, PP, 0.45 mL),
diluted to 200 mL with 85% aq. MeOH, sealed and stored at 5uC
for further purity check by UHPLC-PDA-TOFMS.
UHPLC-PDA-TOFMS Experiments
UHPLC-PDA-TOFMS analyses were performed using an
AcquityTM UPLC chromatograph and a Micromass-LCT Premier
Time of Flight mass spectrometer equipped with an ESI interface
(Waters). For the profiling of the crude extract, analyses on the
generic gradient method were performed using a 15062.1 mm
i.d., 1.7 mm, Acquity BEH C18 UPLC column (Waters). For the
optimized gradient method, a 10062.1 mm i.d., 1.7 mm, Acquity
BEH C18 UPLC column (Waters) was used and for the verification
of the purity and identity of the microfractions, a short analysis was
performed on a 5062.1 mm i.d., 1.7 mm, Acquity BEH C18
UHPLC column (Waters). The analysis conditions are given in
detail in the Text S1.
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Dereplication Procedure
The procedure published by Funari et al. [29] was used for the
dereplication of compounds in the crude extract and identification
of the isolated compounds. For the database search (DNP,
SciFinder), hits were refined by searching for compounds isolated
from Fabaceae species. More details on the dereplication
procedure are given in the Text S1.
Quantitative Microflow NMR Measurements
NMR spectra of the microfractions were recorded on a Varian
INOVA 500 MHz NMR instrument at 25uC, equipped with a
microflow NMR probe (CapNMRTM) and an automated sample
injection unit (One Minute-NMRTM) from Protasis. Remaining
amounts of microfractions (89% of the total microfraction volume,
aliquot C) were diluted in 10 mL of methanol-d4 whereof 8 mL
were injected.
For the quantitative studies, the relaxation delay T1 was
experimentally determined for all protons of genistein to choose
the recycle delay for qNMR acquisition and to determine the 1H
signals suitable for quantification. The protons on cycle B
(T1 = 2.0–2.3 s) and C (T1 = 2.7 s) were fully recovered (time
.5*T1) within a recycle delay of less than 15 s, whereas the
protons on cycle A were only fully recovered after 25 s. A recycle
delay of 20 s was set for qNMR experiments and well resolved 1H
signals on cycle B were chosen for quantification. The optimal
pulse width at 90u was arrayed (at 360u) for every individual
sample and lays between 4.1 and 4.2 ms. FIDs were Fourier
transformed with LB= 0.3 Hz. The resulting spectra were
manually phased, baseline corrected using a 1st order polynomial
function and calibrated to the residual methanol peak at 3.31 ppm
using MestReNova (version 6.01, Mestrelab Research S.L.) The
signals were integrated manually and the concentration was
determined using PULCON [17]. Maleic acid was used as
external standard.
Zebrafish
The transgenic line fli-1:EGFP [23] was obtained from the
Zebrafish International Resource Center at the University of
Oregon (Eugene, Oregon, USA). Zebrafish husbandry, embryo
collection, and embryo and larva maintenance were performed as
previously described [46,47]. For the leukocyte migration assay,
zebrafish embryos at one day post fertilization (dpf) were exposed
to 1-phenyl-2-thiourea (PTU) to suppress melanization (Text S1).
For this assay and for confocal imaging, larvae were anesthetized
with tricaine (Text S1).
The leukocyte migration assay was performed in 24-well
microtiter plates using ten 4 dpf larvae per well in 1 mL of
Danieau’s medium (Text S1). The vascular outgrowth assay was
performed in 96-well microtiter plates using five embryos at 16
hours post-fertilization (hpf) per well in 200 mL of Danieau’s
medium. Extracts and compounds were solubilized in DMSO, and
were added to the Danieau’s medium up to a maximum DMSO
concentration of 1%.
Anti-inflammatory Assay
Prior to assessment of the anti-inflammatory activity of R. viscosa
and its derivatives, in vivo toxicological tests were performed to
establish the maximum tolerated concentration of each sample
(Text S1). Next, a LPS-enhanced leukocyte migration assay was
performed. Briefly, larvae were pre-incubated (1 hour at 28uC,
60.5) with specific concentrations of each sample. Negative
controls, containing only vehicle (1% DMSO), and positive
controls, indomethacin 50–100 mM, were processed in parallel.
After pre-incubation, larvae were anesthetized and subjected to
complete tail transection made 0.5 mm (60.2) from the tip of the
tail of each larvae under microscopy light (Carl Zeiss Stemi
2000C) using a scalpel. Next, tail-cut larvae were briefly rinsed in
Danieau’s medium without tricaine and incubated for seven hours
with specific concentrations of each sample containing 10 mg/mL
LPS (Salmonella typhosa ATCC 10749, Sigma-Aldrich). After this
incubation, larvae were fixed in 4% paraformaldehyde and kept
overnight at 4uC. Fixed larvae were gently washed with PBST
(PBS-1X phosphate buffered saline, Gibco +0.1% Tween 20) and
next subjected to incubation (15 minutes at room temperature)
with 1 mL of freshly prepared staining solution (LeucognostH Pox,
Merck). Evaluation of the migrating leukocytes to the injured
region was done in one side of each larva under light microscopy
and scoring of the migration was assessed according to a 5-point
index of staining intensity. The average of these values for each
experimental group were normalized against the average values of
the control group (1% DMSO) and expressed as RLM, which for
significant anti-inflammatory activity has a cutoff point of RLM
#0.5. All experiments were performed in duplicate, with ten
larvae per condition. Statistical analysis was done using GraphPad
Prism 5 software using one-way analysis of variance (ANOVA).
Angiogenesis Assay
Prior the initiation of ISV outgrowth, fli-1:EGFP embryos at
16 hpf were incubated (32 hours at 28uC, 60.5) with specific
concentrations of extracts and compounds. Negative controls,
containing only vehicle (1% DMSO) were processed in parallel.
The microfraction samples for biological profiling (aliquot A of
each microfraction) were dried, re-solubilized in 3 mL DMSO and
diluted to 150 mL with Danieau’s medium, of which 90 mL were
used for a first screen. Microfractions with 100% inhibitory
activity or exhibiting toxicity were tested at a lower concentration
(1/3 of the initial concentration).
Inhibition of vascular outgrowth along the trunk of every larva
was evaluated under UV microscopy light (MZ10F Leica stereo
microscope) at 48 hpf and scoring of anti-angiogenic activity was
done according to a 5-point index for vascular outgrowth. The
average of the values for each experimental group was normalized
against the average of the values of the control group (1% DMSO),
yielding a relative vascular outgrowth (RVO) score that was then
expressed as percentage of inhibitory activity. All experiments
were performed in duplicate, with five larvae per condition.
Statistical analysis and IC50 curves were done using GraphPad
Prism 6 software using nonlinear regression to fit the data to the
log (inhibitor) vs. response curve (variable slope). Representative
embryos were subjected to confocal imaging (see below).
Confocal Imaging
Confocal imaging (Figure 2 and 5) was carried out using a
Nikon A1R confocal unit (Nikon) mounted on a Ti2000 inverted
microscope (Nikon). For the imaging, 46(0.2 N.A.) and
106(0.45 N.A.) lenses were used. For detecting the fluorescence
of the fish embryos, a 488 nm laser line (CVI Melles Griot) and
detection filters for the range of 515–550 nm were used. Confocal
stacks of the whole fish or the depicted regions were acquired and
projections of the maximum intensity of the 3D volume shown.
During imaging, zebrafish embryos were anesthetized using
0.1 mg/mL tricaine in Danieau’s medium.
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Novel Compound from Rhynchosia viscosa with Anti-
angiogenic Activity
Rhynchoviscin (b). Insufficient material was available to obtain
an optical rotation value. Purity: 80% (determined by NMR). UV
(MeOH) lmax (log e) 304 nm (4.39);
1H NMR (DMSO-d6,
500 MHz, CapNMRTM probe, dH): 0.94/0.97 (3H, s, H-5’’’),
1.18/1.21 (3H, s, H-4’’’), 1.24/1.26 (3H, d, J=6.4 Hz, H-3’’’),
4.40/4.47 (1H, q, J=6.4 Hz, H-2’’’), 5.90 (1H, d, J=1.4 Hz, H-
4’’), 5.99 (1H, s, H-8), 6.03/6.04 (1H, d, J=1.4 Hz, H-6’’), 6.19/
6.23 (1H, s, 3-OH), 6.74 (2H, d, J=8.6 Hz, H-3’/H-5’), 7.20/
7.24 (2H, d, J=8.6, H-2’/H-6’), 9.38 (1H, brs, 4’-OH), 9.63 (2H,
brs, 3’’-OH/5’’-OH), 12.09 (1H, brs, 5-OH). 13C NMR (DMSO-
d6, 500 MHz, CapNMRTM probe, dC): 13.8/14.3 (C-3’’’), 20.8
(C-5’’’), 24.5/25.4 (C-4’’’), 42.6 (C-1’’’), 80.3 (C-3), 90.4 (C-6’’),
90.4/90.6 (C-2’’’), 91.4/91.5 (C-8), 97.3 (C-4’’), 99.8 (C-4a), 105.6
(C-2’’), 113.0 (C-6), 114.5 (C-3’/C-5’), 117.1 (C-2), 124.6 (C-1’),
127.9/128.1 (C-2’/C-6’), 155.5 (C-3’’), 158.2 (C-4’), 161.0 (C-5’’),
161.5 (C-1’’), 163.9 (C-8a), 167.0 (C-7), 192.8 (C-4). ESI-MS (NI
mode): m/z 477.1195 [M-H]– (C26H22O9, calc. m/z 477.1186, D
1.9 ppm).
Detailed structure information on compound a, c, d and e can
be found in the Text S1. NMR spectra for rhynchoviscin are given
in Figure S1.
Supporting Information
Figure S1 NMR Spectra (1H, APT, HSQC, HMBC) of
Rhynchoviscin.
(PDF)
Text S1 Supplementary Information on Materials and
Methods.
(DOC)
Text S2 Supplementary Information on Quantitative
Microflow NMR.
(DOC)
Acknowledgments
We gratefully acknowledge Philippe J. Eugster for the acquisition of
UHPLC-PDA-TOFMS data and for assistance on dereplication, and the
Aquaculture Core Facility of the Biomedical Sciences Group at KU
Leuven. MLCM acknowledges the support of the Vlaamse Interuniversi-
taire Raad (VLIR) linked to the VLIR-UOS project "Pharmacological
Characterization of Medicinal Plants from the South of Ecuador" at the
University of Cuenca, Ecuador. DSM acknowledges the support of the
Vlaamse Interuniversitaire Raad (VLIR) linked to a VLIR-UOS
cooperation program with the Central University "Martha Abreu" from
Las Villas, Santa Clara, Cuba.
Author Contributions
Conceived and designed the experiments: ADC JLW NB PAMdW.
Performed the experiments: NB MLCM ADC JM DSM LM. Analyzed the
data: NB JLW ADC MLCM SM CVE PAMdW LM. Contributed
reagents/materials/analysis tools: ARK MJM. Wrote the paper: NB JLW
ADC MLCM.
References
1. Koehn FE, Carter GT (2005) The evolving role of natural products in drug
discovery. Nat Rev Drug Discovery 4: 206–220.
2. Harvey AL (2008) Natural products in drug discovery. Drug Discov Today 13:
894–901.
3. Newman DJ, Cragg GM (2012) Natural products as sources of new drugs over
the 30 years from 1981 to 2010. J Nat Prod 75: 311–335.
4. Macarron R, Banks MN, Bojanic D, Burns DJ, Cirovic DA, et al. (2011) Impact
of high-throughput screening in biomedical research. Nat Rev Drug Discovery
10: 188–195.
5. Welsch ME, Snyder SA, Stockwell BR (2010) Privileged scaffolds for library
design and drug discovery. Curr Opin Chem Biol 14: 347–361.
6. Butler MS (2004) The role of natural product chemistry in drug discovery. J Nat
Prod 67: 2141–2153.
7. Rose´n J, Gottfries J, Muresan S, Backlund A, Oprea TI (2009) Novel chemical
space exploration via natural products. J Med Chem 52: 1953–1962.
8. Gassner NC, Tamble CM, Bock JE, Cotton N, White KN, et al. (2007)
Accelerating the discovery of biologically active small molecules using a high-
throughput yeast halo assay. J Nat Prod 70: 383–390.
9. Crawford AD, Challal S, Buenafe OE, Harvey AL, Esguerra CV, et al. (2011)
Microgram-scale, in vivo natural product discovery using zebrafish bioassays,
UHPLC-TOF-MS and microflow NMR: Identification of anticonvulsants in the
Philippine medicinal plant Solanum torvum. Planta Med 77: 1348–1349.
10. Marston A (2007) Role of advances in chromatographic techniques in
phytochemistry. Phytochemistry 68: 2786–2798.
11. Eldridge GR, Vervoort HC, Lee CM, Cremin PA, Williams CT, et al. (2002)
High-throughput method for the production and analysis of large natural
product libraries for drug discovery. Anal Chem 74: 3963–3971.
12. Williams RB, Martin SM, Hu JF, Garo E, Rice SM, et al. (2012) Isolation of
apoptosis-inducing stilbenoids from four members of the Orchidaceae family.
Planta Med 78: 160–165.
13. Johansen KT, Wubshet SG, Nyberg NT, Jaroszewski JW (2011) From
retrospective assessment to prospective decisions in natural product isolation:
HPLC-SPE-NMR analysis of Carthamus oxyacantha. J Nat Prod 74: 2454–2461.
14. Dalisay DS, Rogers EW, Edison AS, Molinski TF (2009) Structure elucidation at
the nanomole scale. 1. Trisoxazole macrolides and thiazole-containing cyclic
peptides from the nudibranch Hexabranchus sanguineus. J Nat Prod 72: 732–738.
15. Espina R, Yu L, Wang J, Tong Z, Vashishtha S, et al. (2009) Nuclear magnetic
resonance spectroscopy as a quantitative tool to determine the concentrations of
biologically produced metabolites: Implications in metabolites in safety testing.
Chem Res Toxicol 22: 299–310.
16. Barantin L, LePape A, Akoka S (1997) A new method for absolute quantitation
of MRS metabolites. Magn Reson Med 38: 179–182.
17. Wider G, Dreier L (2006) Measuring protein concentrations by NMR
spectroscopy. J Am Chem Soc 128: 2571–2576.
18. Giera M, Heus F, Janssen L, Kool J, Lingeman H, et al. (2009)
Microfractionation revisited: A 1536 well high resolution screening assay. Anal
Chem 81: 5460–5466.
19. Zon LI, Peterson RT (2005) In vivo drug discovery in the zebrafish. Nat Rev
Drug Discovery 4: 35–44.
20. Crawford AD, Esguerra CV, de Witte PAM (2008) Fishing for drugs from
nature: Zebrafish as a technology platform for natural product discovery. Planta
Med 74: 624–632.
21. Hu JF, Yoo HD, Williams CT, Garo E, Cremin PA, et al. (2005) Miniaturization
of the structure elucidation of novel natural products - two trace antibacterial
acylated caprylic alcohol glycosides from Arctostaphylos pumila. Planta Med 71:
176–180.
22. Marrero-Ponce Y, Siverio-Mota D, Ga´lvez-Llompart M, Recio MC, Giner RM,
et al. (2011) Discovery of novel anti-inflammatory drug-like compounds by
aligning in silico and in vivo screening: The nitroindazolinone chemotype.
European Journal of Medicinal Chemistry 46: 5736–5753.
23. Lawson ND, Weinstein BM (2002) In vivo imaging of embryonic vascular
development using transgenic zebrafish. Dev Biol 248: 307–318.
24. Crawford AD, Liekens S, Kamuhabwa AR, Maes J, Munck S, et al. (2011)
Zebrafish bioassay-guided natural product discovery: Isolation of angiogenesis
inhibitors from East African medicinal plants. PLoS ONE 6: e14694.
25. Eugster PJ, Wolfender JL (2012) UHPLC in natural products analysis. UHPLC
in life sciences: The Royal Society of Chemistry. 354–386.
26. Guillarme D, Grata E, Glauser G, Wolfender JL, Veuthey JL, et al. (2009) Some
solutions to obtain very efficient separations in isocratic and gradient modes
using small particles size and ultra-high pressure. J Chromatogr, A 1216: 3232–
3243.
27. Veitch NC (2009) Isoflavonoids of the Leguminosae. Nat Prod Rep 26: 776–802.
28. Guillarme D, Nguyen D, Rudaz S, Veuthey JL (2008) Method transfer for fast
liquid chromatography in pharmaceutical analysis: Application to short columns
packed with small particle. Part II: Gradient experiments. Eur J Pharm
Biopharm 68: 430–440.
29. Funari CS, Eugster PJ, Martel S, Carrupt PA, Wolfender JL, et al. (2012) High
resolution ultra high pressure liquid chromatography–time-of-flight mass
spectrometry dereplication strategy for the metabolite profiling of Brazilian
Lippia species. J Chromatogr, A 1259: 167–178.
30. Kind T, Fiehn O (2007) Seven golden rules for heuristic filtering of molecular
formulas obtained by accurate mass spectrometry. BMC Bioinf 8: 105.
31. Buckingham J (2012) Dictionary of Natural Products on DVD. Version 21:1:
Chapman & Hall/CRC Press.
32. Caligiani A, Palla G, Maietti A, Cirlini M, Brandolini V (2010) 1H NMR
fingerprinting of soybean extracts, with emphasis on identification and
quantification of isoflavones. Nutrients 2: 280–289.
Microscale Natural Product Discovery in Zebrafish
PLOS ONE | www.plosone.org 12 May 2013 | Volume 8 | Issue 5 | e64006
33. Hanawa F, Tahara S, Mizutani J (1991) Isoflavonoids produced by Iris
pseudacorus leaves treated with cupric chloride. Phytochemistry 30: 157–163.
34. Tahara S, Ingham JL, Hanawa F, Mizutani J (1991) 1H NMR chemical shift
value of the isoflavone 5-hydroxyl proton as a convenient indicator of 6-
substitution or 2’-hydroxylation. Phytochemistry 30: 1683–1689.
35. Kinoshita T, Saitoh T, Shibata S (1978) A new isoflavone from licorice root.
Chem Pharm Bull 26: 141–143.
36. Akiyama T, Ishida J, Nakagawa S, Ogawara H, Watanabe S, et al. (1987)
Genistein, a specific inhibitor of tyrosine-specific protein-kinases. J Biol Chem
262: 5592–5595.
37. Sadowska-Krowicka H, Mannick EE, Oliver PD, Sandoval M, Zhang XJ, et al.
(1998) Genistein and gut inflammation: Role of nitric oxide. Proc Soc Exp Biol
Med 217: 351–357.
38. Si HW, Liu DM (2007) Phytochemical genistein in the regulation of vascular
function: New insights. Curr Med Chem 14: 2581–2589.
39. Fotsis T, Pepper M, Adlercreutz H, Fleischmann G, Hase T, et al. (1993)
Genistein, a dietary-derived inhibitor of in vitro angiogenesis. PNAS 90: 2690–
2694.
40. Fotsis T, Pepper MS, Montesano R, Aktas E, Breit S, et al. (1998)
Phytoestrogens and inhibition of angiogenesis. Baillieres Clin Endocrinol Metab
12: 649–666.
41. Farina HG, Pomies M, Alonso DF, Gomez DE (2006) Antitumor and
antiangiogenic activity of soy isoflavone genistein in mouse models of melanoma
and breast cancer. Oncol Rep 16: 885–891.
42. Wang B, Zou Y, Li H, Yan H, Pan JS, et al. (2005) Genistein inhibited retinal
neovascularization and expression of vascular endothelial growth factor and
hypoxia inducible factor 1a in a mouse model of oxygen-induced retinopathy.
J Ocul Pharmacol Ther 21: 107–113.
43. Zhou GX, Jiang RW, Chen Y, Ye WC, Shi JG, et al. (2007) Daphnogirins A and
B, two biflavones from Daphne giraldii. Chem Pharm Bull 55: 1287–1290.
44. Glauser G, Boccard J, Rudaz S, Wolfender JL (2010) Mass spectrometry-based
metabolomics oriented by correlation analysis for wound-induced molecule
discovery: identification of a novel jasmonate glucoside. Phytochem Anal 21: 95–
101.
45. Vargas S, Ndjoko Ioset K, Hay AE, Ioset JR, Wittlin S, et al. (2011) Screening
medicinal plants for the detection of novel antimalarial products applying the
inhibition of b-hematin formation. J Pharmaceut Biomed 56: 880–886.
46. Westerfield M (1994) The zebrafish book: a guide for the laboratory use of
zebrafish (Brachydanio rerio). Eugene: University of Oregon Press.
47. Nu¨sslein-Volhard C, Dahm R (2002) Zebrafish: A practical approach; Hames
BD, editor. Oxford: Oxford University Press. 303 p.
Microscale Natural Product Discovery in Zebrafish
PLOS ONE | www.plosone.org 13 May 2013 | Volume 8 | Issue 5 | e64006
